Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Manganese MRI for Blood-Brain-Barrier Breakdown in Drug-Resistant Epilepsy
NCT02531880Phase 1Recruiting
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Nov 2024
- Primary completion
- Jul 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mangafodipir in epilepsy (2 arms), sponsored by National Institute of Neurological Disorders and Stroke. Primary endpoints: Safety profile of mangafodipir administration and Utility of MEMRI and/or DCE-MRI in identifying focal BBBD. Started Nov 2024; status: recruiting.
02
Drugs
mangafodipir
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT02531880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02531880.